Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Eraxis/Ecalta (anidulafungin) vs Cancidas (caspofungin) in Candida Deep Tissue Infection
2008-005278-11Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Dec 2008
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in invasive candidiasis and candidiasis comparing Anidulafungin (Eraxis/Ecalta) with Caspofungin (Cancidas) (2 arms). Primary endpoint: Global response at end of intravenous therapy (EOIVT) in MITT evaluable population. Started Dec 2008; status: terminated.
02
Drugs
anidulafungincaspofungin
03
Conditions
invasive candidiasiscandidiasis
Beyond the preview
Go deeper on 2008-005278-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005278-11.